TCID,UbiquitinC-terminalHydrolase-L3(UCH-L3)Inhibitor
如果您對該產(chǎn)品感興趣的話,可以
產(chǎn)品名稱: TCID,UbiquitinC-terminalHydrolase-L3(UCH-L3)Inhibitor
產(chǎn)品型號: M60197-2s
產(chǎn)品展商: 其它品牌
產(chǎn)品文檔: 無相關(guān)文檔
簡單介紹
TCID,UbiquitinC-terminalHydrolase-L3(UCH-L3)Inhibitor
TCID,UbiquitinC-terminalHydrolase-L3(UCH-L3)Inhibitor
的詳細(xì)介紹
Product Information
Molecular Weight: |
283.92 |
Formula: |
C9H2Cl4O2 |
Purity: |
≥98% |
CAS#: |
30675-13-9 |
Solubility: |
DMSO up to 50 mM |
Chemical Name: |
4,5,6,7-Tetrachloro-1H-Indene-1,3(2H)-dione |
Storage: |
Powder: 4oC 1 year.
DMSO: 4oC 3 month;
-20oC 1 year. |
Biological Activity:
TCID is a novel potent and selective inhibitor of ubiquitin C-terminal hydrolase-L3 (UCH-L3) with an IC50 ~0.6 μM. It has ~125-fold greater selectivity over UCH-L1 (ubiquitin C-terminal hydrolase L1, IC50 ~75 μM). TCID can diminish glycine transporter GlyT2 ubiquitination in brain stem and spinal cord primary neurons.
How to Use:
- In vitro: TCID was used at 10-30 μM final concentration in various in vitro assays.
- In vivo: n/a
Reference:
- 1. Liu Y, et al. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. (2003) Chem Biol. 10(9):837-46.
- 2. de Juan-Sanz J, et al. Constitutive endocytosis and turnover of the neuronal glycine transporter GlyT2 is dependent on ubiquitination of a C-terminal lysine cluster. (2013) PLoS One. 8(3):e58863.
Products are for research use only. Not for human use.